EPISODE · May 4, 2026 · 1 MIN
Cryoport's Q1 2025: Strong Growth & Strategic Partnership
from The Daily News Now! Business
Cryoports Q1 2025 earnings showcase strength in cell and gene therapy logistics. Life Sciences Services revenue surged 17% YoY, with commercial therapies soaring 33%. The company now supports 20 commercial products and 711 clinical trials. A strategic partnership with DHL, selling CryoPDP for $195M, focuses core services and expands global presence. Analysts praise momentum, trial adds, and diversification into BioStorage and BioServices. IntegriCell cryopreservation gains traction, with facilities open in Houston and Belgium. Execs anticipate positive adjusted EBITDA for 2025, positioning Cryoport as a leader in regenerative medicine. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/c4bd315908ff9c4a
NOW PLAYING
Cryoport's Q1 2025: Strong Growth & Strategic Partnership
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m